[Lip cyanosis in dapsone therapy: should the dosage be reduced?].
Dirk
D
Stichtenoth
D003490:Cyanosis / Q000139:chemically induced*; D003622:Dapsone / Q000008:administration & dosage* / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005493:Folic Acid Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000188:drug therapy*; D016460:Granuloma Annulare / Q000188:drug therapy*; D006452:Hemoglobinometry; D006801:Humans; D008047:Lip Diseases / Q000139:chemically induced*; D008708:Methemoglobinemia / Q000139:chemically induced*; D008875:Middle Aged; D012871:Skin Diseases / Q000188:drug therapy*
D005493:Folic Acid Antagonists; D003622:Dapsone